Previous 10 | Next 10 |
home / stock / giflf / giflf news
2023-11-29 08:21:29 ET More on Grifols Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript Grifols: Cheap For A Reason Historical earnings data for Grifols, S.A. Financial information for Grifols, S.A. Historical earnings data for Grifols, S.A. ...
2023-11-02 22:33:06 ET Grifols, S.A. (GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo -...
2023-07-27 15:45:16 ET Grifols, S.A. (GRFS) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Ca...
2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...
2023-05-09 22:36:06 ET Grifols, S.A. (GRFS) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participa...
We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...
FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...
Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona Company Name:
GIFLF Stock Symbol:
OTCMKTS Market:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
New York City, NY: April 09, 2020 – Recent Research and Future Market Potential of Automated Blood Processing Equipment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the report is to offer updates and inform...